There is debate in the tobacco control literature about the value of a medical model in reducing smokingrelated harm.
INTRODUCTION
Some in the tobacco control field have argued that the increasing medicalisation of smoking cessation could deter unassisted quit attempts 1 or lead to a belief in 'magic bullets' for tobacco dependence. 2 A broad critique of medicalisation is that it "places excessive emphasis on the biological and individual determinants of disease at the expense of a more holistic perspective that emphasises the social, cultural, and environmental contributions to disease and illness''. 3 This paper outlines the historical context in which smoking came to be described and treated as a medical problem; examines the extent to which smoking has become medicalised in high-income countries; and identifies a number of factors that have limited the reach of a biomedical approach to reducing tobacco smoking. The paper concludes with a discussion about the potential of ecigarettes to disentangle nicotine from therapeutic approaches to cessation, thereby creating a nonmedical way to quit smoking that does not require nicotine abstinence.
BIOMEDICAL DEFINITIONS OF TOBACCO DEPENDENCE: FROM 'BAD HABIT' TO 'NICOTINE ADDICTION'
Medicalisation occurs when a social issue is defined as a medical condition. This can occur at the conceptual, institutional or interactional level. 4 The conceptual level refers to the application of a medical definition or label. Medicalisation at the institutional level involves the uptake of medical definitions and models by key institutions, such as in treatment guidelines for health services. The interactional level involves communication between a healthcare provider and his/her patients. Examples include diagnosing a patient with a disorder, or prescribing medication. Medicalisation is rarely complete, and may occur at one level but have little impact at another. 4 Power differentials between groups are central to medicalisation theory. Early work on medicalisation emphasised the power of the medical profession (ie, doctors/physicians) to transform social deviance into medical illness. 5 More recent work describes the way that medicalisation appears to be accelerating under the influence of the pharmaceutical and health insurance industries. 6 Some believe that 'technoscientific innovations' such as genomics and biotechnology have fundamentally transformed the medical arena in a process termed biomedicalisation, 6 although there is a debate about whether biomedicalisation fundamentally departs from medicalisation or represents a shift of influence and power. 7 In tobacco control, medical definitions of tobacco smoking have become more prevalent over time, beginning with the labelling of smoking as an addiction. Early in the 20th century, tobacco use was seen as problematic by some, but it was not perceived as an inebriating drug like alcohol or opiates, so tobacco use was not categorised as a 'disease' like other addictive drugs. 8 While some pointed to features of smoking that signalled addiction, 9 the term 'addiction' was not widespread and addiction was not recognised as a factor in smoking in official government documents. As public awareness of the health risks of smoking increased in the 1950 and 1960s, more smokers attempted to quit, leading to the observation that many smokers had difficulty in stopping.
Nonetheless, it was not until 1988 that the US Surgeon General concluded that tobacco smoking was addictive, primarily because of the reinforcing effects of nicotine. Cigarettes were redefined as a 'delivery device' for nicotine, an addictive drug "in the same sense as … heroin and cocaine". 10 The move from describing smoking as 'habituation' in the 1964 report to 'nicotine addiction' in 1988 was influenced by neuroscience insights about how nicotine worked in the brain and evidence that nicotine replacement therapy (NRT) reduced cravings for cigarettes. 11 Diagnostic criteria were another domain in which medical labels began to be applied to smoking. While the tobacco industry claimed that it would be 'ridiculous' to label a common everyday behaviour as a mental disorder, 12 the arbiters of the Diagnostic and Statistical Manual (DSM) included 'tobacco dependence' as a diagnostic category in DSM-III. The 1987 revision renamed 'tobacco dependence' as 'nicotine dependence', a label retained in DSM-IV. 13 The diagnostic criteria for nicotine dependence were based on those for other drugs: tolerance, withdrawal symptoms, compulsive use and use despite negative consequences. In DSM-V, 'nicotine dependence' was renamed 'tobacco use disorder'. Very similar diagnostic criteria were applied with dependence diagnosed along a continuum of severity, from mild, moderate to severe dependence.
DSM-V has been criticised for being more 'expansive' than previous versions as all tobacco users can now be diagnosed with tobacco use disorder. 12 Once critic noted the pharmaceutical industry's influence in redefining smoking as a psychiatric disorder which implies the need for medical, specifically pharmaceutical, treatment and argued that "the psychiatric diagnosis of tobacco use disorder is more about the current social, political, and economic context of US medical and public health approaches to cigarettes than a valid description of a disease state". 12 
PHARMACOTHERAPY FOR SMOKING CESSATION AND THE ROLE OF THE HEALTH PROFESSIONAL
Another key component of medicalisation is the availability and promotion of medical treatments, such as pharmacotherapies for smoking cessation. NRT, in the form of gum, was first developed in the 1960s to reduce cravings for cigarettes when quitting and prevent relapse. Elam has written a comprehensive history of the development of NRT, including differences between countries.
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He describes 'two competing scripts' about NRT, with debate occurring over whether NRT should be marketed as an alternative and safer way of using nicotine (a harm reduction approach) or solely as a medicine for smoking cessation (a medical approach). 11 The latter came to dominate after clinical trials demonstrated NRT's efficacy in smoking cessation. 14 15 NRT is now available in multiple forms that vary in strength and speed of nicotine delivery. While initially available only via prescription, most forms of NRT are now available over the counter in pharmacies and general retailers in many countries. The WHO has added NRT to the Model List of Essential Medicines 16 to encourage governments to provide NRT at low cost. Two non-nicotine prescription-only medications for smoking cessation are also widely available: bupropion and varenicline. Both medicines are supported by clinical trial data, with varenicline demonstrating greater efficacy than bupropion or nicotine patches. 17 18 Other potential smoking cessation medicines have been or are currently being investigated. 19 The use of smoking cessation pharmacotherapies has increased steadily since their introduction. In Australia, the use of cessation pharmacotherapy in a quit attempt in the previous year increased from 32% in 2002 to 52% in 2008. 20 Similarly, in the UK, 53.6% of those who had quit in the previous year had used a cessation aid in 2010 21 However, there is poor treatment adherence, with many users prematurely discontinuing use. [22] [23] [24] The widespread use of pharmacotherapy contrasts with low uptake of behavioural support for smoking cessation, despite evidence that the most effective way to quit smoking is to use both.
14 Research in numerous countries shows low use of telephone support services for quitting. 20 25 26 A 2011 UK report found that 54% of smokers who had made a quit attempt in the past year had used pharmacotherapy, but only 5.5% had attended cessation clinics which provide comprehensive support. 21 Poor adherence to NRT in the community setting and low use of behavioural support has led to arguments that a medical approach to smoking cessation may not be the optimal way to deal with the tobacco epidemic. 1 
SMOKING AS A CHRONIC DISEASE
Tobacco treatment guidelines in the USA, Australia and the UK recommend that health professionals identify smokers, provide brief cessation advice and prescribe pharmacotherapy. [27] [28] [29] Some authors have recently recommended that health professionals should provide cessation treatment to all their smoking patients, regardless of their desire or 'readiness' to quit. [29] [30] [31] These authors argue that smoking should be treated as a 'chronic disease' because smokers' propensity to relapse makes smoking like hypertension, diabetes or high cholesterol. The US Public Health Services Guidelines go further, stating that "Tobacco dependence is a chronic disease that often requires repeated intervention and multiple attempts to quit". 27 Tobacco smoking is increasingly portrayed as a risk factor for disease, as well as a disease in itself. 32 Animal research and human neuroimaging studies that have identified the neurochemical changes in the brain related to prolonged use of cocaine and heroin have encouraged the use of the 'disease' label for smoking. 33 34 The same approach was later applied to nicotine dependence. The concept that addiction is a disease is not new, but the idea that it has a specific neurobiological basis that can be pinpointed in the brains of smokers, allowing targeted drug treatment, is a more recent development. Older models of addiction framed drug dependence as a disease of the will, 35 while newer models describe smoking as a 'chronic brain disorder.' 36 Proponents of this idea argue that a focus on biological factors will reduce moral judgements about addicted individuals, enable more humane public policy responses to addiction, and lead to improved treatment of addiction. 37 A number of novel neurobiological treatments for smoking cessation have been developed or proposed, such as transcranial magnetic stimulation. This non-invasive procedure involves placing a magnetic device near the surface of the skull to stimulate neurons in targeted areas of the brain. Some studies suggest that this treatment may reduce cravings for cigarettes in the short term, 38 39 but there is little evidence of long-term efficacy. Brain scans and pharmacogenetics may also be used in the future to identify those at risk of relapse to smoking and to match individuals to the most effective interventions. [40] [41] [42] 
CRITIQUES OF THE BIOMEDICALISATION OF TOBACCO SMOKING
While proponents of the medical approach to smoking are optimistic about its potential to produce better cessation aids, opponents are concerned about potential negative impacts of viewing and treating tobacco dependence as a disease. Despite the effectiveness of pharmacotherapy for smoking cessation in clinical trials, there are criticisms of the way these pharmaceutical aids are promoted. 1 Critics point out that most smokers who use cessation pharmacotherapy fail to quit and that most clinical trials demonstrating the effectiveness of pharmacotherapies for smoking cessation are sponsored by pharmaceutical manufacturers. 1 43 Advocates of a medical model of smoking counter that even though these interventions only succeed in a minority of smokers, these treatments are cost-effective when compared to other health interventions. 44 Some have argued that more smokers should be encouraged to use them: "If there is a major failing in the UK approach, it is not that it has medicalised smoking, but that it has not done so enough". 45 Critics of a biomedical model of smoking also argue that it neglects the fact that most smokers quit unaided, and may unwittingly make quitting seem more difficult than it is by eroding selfefficacy and agency. 1 46 A focus on the addicted smoker's brain, it is argued, could lead to: a diminution of the role of choice in public understandings of smoking; a neglect of structural and social factors that sustain smoking; and the potential for discrimination based on the neuromolecular status of individuals. 3 A shift in emphasis from the cigarette to the smoker may also deflect attention from the role of the tobacco industry and its dangerous products. Indeed, the tobacco companies were strong supporters of genetic research on addiction as a strategy to deflect blame for the health consequences of smoking from the cigarette to the 'genetic constitution' of the smoker. 47 A focus on the treatment of individuals may reduce the emphasis on broader, effective population-based measures, such as increasing tobacco taxes and banning smoking in public spaces. 48 Medicalised understandings of addiction may also increase the stigma directed towards addicted individuals. 49 50 It has been argued that brain-based explanations of smoking are responsible for 'remoralizing' addiction by portraying drug users as 'brain hostages' who have lost control of themselves. 51 At the same time, drug users are encouraged to take responsibility for protecting their brains and working to achieve a healthy state. Constant vigilance is required to "avoid being terrorised by our own neural circuitry gone awry". 51 These criticisms of the medicalisation of addiction closely align with the 'darker sides' of medicalisation described by Conrad and Schneider, 4 namely the individualisation of social problems and the dislocation of individual responsibility.
FACTORS LIMITING THE BIOMEDICALISATION OF SMOKING
There are a number of factors that are likely to limit the influence of a medical approach to smoking. First, the tobacco control field emerged from epidemiology and public health. 8 Consequently, a medical approach has not displaced the population-based measures that remain central to the field's research and policy advocacy. The WHO Framework Convention on Tobacco Control has a strong emphasis on population-based measures, with only one article on treatment for smoking cessation. 52 Since many of the countries with increasing smoking prevalence have limited resources, an emphasis on cost-effective population-level interventions is vital. For countries in the early stages of the tobacco epidemic, the widespread treatment of individual smokers with pharmacotherapy is unlikely to be financially viable, 1 although some have advocated for NRT as a cost-effective medication even in lowincome countries. 53 A second factor limiting the biomedicalisation of smoking is nicotine's ambiguous place among other drugs. 54 Nicotine has only mild psychoactive effects, and regular smokers do not become intoxicated. Smoking does not usually adversely affect an individual's ability to function in everyday life or cause the social problems associated with other substance use. Many adverse health effects often only emerge after decades of smoking. The intensity of medical treatment for addiction to alcohol or illicit drugs usually differs from that offered for nicotine. Treatment for other drugs often involves supervised detoxification, extended rehabilitation programmes or long-term substitution programmes (eg, methadone maintenance therapy for opioid dependence). It is very rare for smokers to receive inpatient care solely for their smoking, although there are exceptions. 55 Many healthcare practitioners are unenthusiastic about a medical approach to smoking cessation. Despite the clinical recommendations described above, surveys in a number of countries show that most smokers are not offered assistance to quit by their physicians. 20 21 25 Smokers also appear resistant to using cessation aids or seeking professional assistance to quit. Many do not believe that NRT is effective for smoking cessation, [56] [57] [58] or reducing cigarette cravings. 59 Research with former smokers found that those who quit unassisted prioritised 'lay knowledge' based on their own experiences and that of family and friends, over medical professionals' advice on cessation treatment efficacy. 60 While some clinicians see negative perceptions of NRT as misperceptions that should be corrected, 57 59 they may be based on the past experiences of many smokers who have failed to quit despite using pharmacotherapies. More research is required on how medical practitioners judge the efficacy of cessation pharmacotherapies, and how this may be influenced by comparison with the efficacy of other routinely prescribed medications.
Many smokers are also concerned about the health risks of cessation pharmacotherapies. Smokers mistakenly believe that nicotine causes cancer, 57 61-63 probably because of the close association between nicotine, cigarettes and the health harms of smoking. 57 It may be difficult for people to understand that the harmful effects of cigarette smoking are much reduced when they obtain their nicotine in the form of NRT. 57 61-63 Furthermore, some in public health have highlighted concerns about nicotine's safety for long-term use in opposing substitution of cigarettes with 'cleaner' forms of nicotine, such as snus and e-cigarettes. 64 This is despite the fact that any harm caused by long-term nicotine use is likely to be minimal compared to the severe health risks of smoking cigarettes. 65 Research on public opinions shows an increase over time in the belief that nicotine causes cancer. 66 Concerns about health risks are even more pronounced in relation to prescription pharmacotherapies for smoking cessation. Smokers commonly believe that these have serious and life-threatening side effects, 59 67 while ignoring the substantial risk of dying from continuing to smoke.
Finally, qualitative studies report that willpower and personal responsibility are key terms in smokers' discourses about smoking and cessation. 59 60 68 69 Assisted cessation conflicts with smokers' conceptualisations of quitting that emphasise the importance of internal strength and willpower. Smokers often described smoking as having a behavioural or psychological aspect that cessation medications do not address. 59 70 71 The key finding in these studies is that smokers believe that the physiological aspect of their addiction only partly explains why they continue to smoke. This finding is also supported by survey research with smokers which found low levels of agreement that an inability to quit was caused by biological factors (21%) or that smoking was a 'disease' (10%). 72 This suggests that biomedical conceptualisations of smoking do not strongly align with the way that smokers understand their own smoking.
E-CIGARETTES AND THE ROLE OF NICOTINE ADDICTION IN THE TOBACCO 'ENDGAME'
E-cigarettes have been described as a 'disruptive technology' with the potential to make cigarettes obsolete. 73 They are controversial because opponents fear that the hand-to-mouth action and exhalation of a visible 'vapour' could renormalise smoking.
Critics of e-cigarettes stress their unknown long-term health risks and their potential role as a gateway into smoking for young people. 74 As a non-therapeutic product, e-cigarettes present an 'ideological challenge' to the dichotomisation of nicotine into the 'bad' form sold by tobacco companies and the 'good' form sold as medicines by pharmaceutical companies. 75 E-cigarettes provide a way to consume nicotine for non-therapeutic purposes, without incurring the harms caused by smoking tobacco. As such, they occupy an ambiguous product category that is neither a tobacco product nor a medical aid for cessation. 76 Consequently, ecigarettes could lead to a future in which nicotine becomes 'disarmed' 11 and dissociated from both tobacco and medicines. As a recreational product that is much safer and more socially acceptable than cigarettes, e-cigarettes could facilitate the de-medicalisation of non-tobacco nicotine use.
Alternatively, e-cigarettes could be incorporated into medical models of smoking cessation. A medical or treatment-focused approach has generally been more open to using nicotine substitution for tobacco harm reduction, such as in the UK, where ecigarettes are largely viewed as an opportunity to help existing smokers to quit. While the MHRA (UK medicines regulator) attempted to regulate all e-cigarettes as medical products, a 'dual track' regulatory model was ultimately adopted allowing manufacturers to choose either the medicines licensing route or compliance with the European Union's Tobacco Products Directive. Only one e-cigarette has gained MHRA approval, but it is yet to be released to market. 77 Nevertheless, e-cigarettes are being incorporated into the medical model of smoking cessation in the UK, with smoking cessation clinics encouraged to be "open to e-cigarette use in people keen to try them to help them quit". Specific recommendations in this regard have been disseminated. 78 In the USA, the Food and Drug Administration (FDA) also originally moved to regulate e-cigarettes as therapeutic devices subject to the same stringent regulations as are applied to medicines. The vaping industry opposed this on the grounds that it would make it prohibitively expensive to obtain approval for their devices for all but the most well-resourced companies, such as those owned by tobacco and pharmaceutical companies. This argument is supported by the fact that the only company so far to gain medicines licensing for an e-cigarette is a wholly-owned subsidiary of a tobacco company. 77 The FDA has now proposed to regulate e-cigarettes as tobacco products, 79 although this proposal is also being legally challenged. 80 The lack of commercial interest in gaining medicines approval for e-cigarettes has meant that countries that have restricted the sale of non-tobacco nicotine products to a medicines framework have had to decide between continuing what is effectively prohibition on nicotine-containing e-cigarettes, or amending their regulations to permit a legal market in non-therapeutic nicotine products. Recent announcements by the New Zealand and Canadian governments suggest that they are taking the latter option. 81 82 A rescheduling application has also been submitted to the Australian Therapeutic Goods Administration that could pave the way for nicotine vaping solutions to be sold in Australia as a non-therapeutic product, similar to smoked tobacco. 83 It might be assumed that regulating e-cigarettes as a consumer product will make them more appealing than NRT to those who reject adopting a sick role in relation to their smoking. In England, the rise in vaping appears to have reduced smoking prevalence by increasing the success rate of quit attempts rather than by increasing the number of smokers making a quit attempt. 84 While e-cigarettes appear to have partially displaced use of some cessation aids ( prescribed NRT), 85 overall they appear to have increased the proportion of quit attempts in England that are assisted. Similarly, a US study also found that e-cigarettes appear to have increased the rate of assisted cessation by 50%. 86 Many vapers strongly oppose regulating e-cigarettes as medicinal products. 87 However, the reason for using e-cigarettes most commonly reported is 'to quit smoking', 88 suggesting that many vapers have primarily used e-cigarettes as a type of quitting tool, albeit an unapproved one. To appeal to smokers who are not trying to quit, e-cigarettes may need to become more widely accepted as a superior nicotine product, rather than just being perceived as a less harmful ersatz cigarette or a cessation tool. Clearly, for the majority of smokers, this is yet to occur and may require both technological advances to improve nicotine delivery and a shift in public attitudes towards nicotine. However, such improvement could also increase concerns about their addictiveness and use by non-smokers. Further regulation of tobacco cigarettes to make them less attractive compared to e-cigarettes, such as by increasing cost, reducing nicotine content and/or prohibiting flavours and other additives, could help improve the relative attractiveness of e-cigarettes as an alternative nicotine product. Competing ideas about the future role of nicotine in tobacco control [89] [90] [91] are contributing to strong debates about the optimal regulatory approach for these products in many counties.
CONCLUSION
The strongest form of medicalisation portrays smoking as a 'chronic brain disorder' in which individuals lose control of their behaviour and need medication to treat their 'relapsing disease'. This view has prompted research into increasingly sophisticated biotechnological strategies for treating smoking, such as transcranial magnetic stimulation, pharmocogenetics and brain scans. While this approach has concerned some commentators, we have argued that a number of factors make it unlikely that a medical model will become dominant in tobacco control. We agree with others who describe the medicalisation of smoking as 'partial and fragmented.' 92 The medical definitions of smoking adopted by some influential institutions are not reflected in the way that smokers understand their smoking, and have not affected interactions between doctors and their smoking patients. Enthusiasm for a biomedical model of smoking should be tempered by the importance that smokers still place on the roles of willpower and choice, and the continued success of population level strategies in tobacco control. While a medical approach to smoking cessation will continue to play a role in reducing tobacco-related disease, it is unlikely to ever become the dominant approach.
The regulatory decisions that many countries are currently making about e-cigarettes will shape their influence on the medicalisation of smoking, and potentially the demedicalisation of nicotine use. The regulation and promotion of e-cigarettes as therapeutic devices could limit the attractiveness of e-cigarettes to smokers who do not see their smoking as a medical problem in need of 'treatment.' The UK approach, where e-cigarettes are regulated as consumer products, as well as incorporated into cessation treatment by health professionals, is a promising model. However, increasing the appeal of vaping as a substitute for smoking for non-treatment-seeking smokers is a challenge that will need to be overcome if public health is to put this technology 'to full use'. 93 While the future role of e-cigarettes remains unclear, they are likely to have implications for tobacco control policy, how nicotine is understood by the public and the role played by health professionals in smoking cessation.
What this paper adds ▸ The medicalisation of smoking has occurred to some extent, but there are factors that limit its influence in tobacco control. ▸ E-cigarettes have the potential to demedicalise nicotine, though this will be influenced by the outcome of current regulatory debates and decisions.
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